araag2/HINT huggingface dataset:
Clinical trial NCT01149421 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2189265, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes taking 1 or more oral diabetes medications and have taken these
             medications for at least 1 month prior to screening

          -  Glycosylated hemoglobin (HbA1c) value ≥7% and ≤9.5% at screening

          -  Mean blood pressure >90/60 millimeters of mercury (mmHg) and <140/90 mmHg at screening

          -  If treated for hypertension, are taking 3 or less antihypertensive medications and
             have been taking these medications for at least 1 month prior to screening

          -  Stable weight for 3 months prior to screening

          -  Body mass index (BMI) greater than or equal to 23 kilogram-meter squared (kg/m^2)

          -  Willing to wear an ambulatory blood pressure monitoring device for at least 24 hours
             on multiple occasions

          -  Women of childbearing potential must test negative for pregnancy and be willing to use
             a reliable method of birth control

          -  Male participants must use a reliable method of birth control

        Exclusion Criteria:

          -  Myocardial infarction, stroke, or hospitalization for heart failure within 3 months
             prior to screening, or heart failure Class III or IV at screening

          -  Ongoing or history of frequent intermittent tachyarrhythmia

          -  Resting heart rate <60 beats per minute (bpm) or >100 bpm at screening

          -  Work rotating shifts or work during the hours of 2200 to 0700

          -  Chronic insulin therapy

          -  Use of a glucagon-like peptide 1 (GLP-1) receptor agonist within 3 months prior to
             screening, or a dipeptidylpeptidase-IV (DPP-IV) inhibitor within 2 weeks prior to
             screening

          -  Nondominant arm circumference >42 centimeter (cm)

          -  Use of drugs to promote weight loss

          -  Chronic use of systemic steroids

          -  Gastric emptying abnormality or bariatric surgery

          -  Hepatitis, other liver disease, or alanine transaminase (ALT) >3 times the upper limit
             of normal

          -  Acute or chronic pancreatitis

          -  Severe renal impairment

          -  Active autoimmune disease or uncontrolled endocrine abnormality

          -  Self or family history of thyroid cancer, medullary C-cell hyperplasia, or type 2A or
             2B multiple endocrine neoplasia

          -  Calcitonin value greater than or equal to 20 picograms per milliliter (pg/ml) at
             screening

          -  Transplanted organ except corneal transplants

          -  Active or untreated cancer or in remission <5 years, except skin, in situ cervical, or
             prostate cancer

          -  Sickle-cell disease, hemolytic anemia, or another hematological condition that may
             interfere with HbA1c testing
Clinical trial NCT00065572 (phase 2, status: suspended)
Conditions: carcinoma, renal cell, kidney neoplasms
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: zd6126, placebo
SMILES: COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=C2C=CC(OP(O)(O)=O)=C3)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed metastatic renal cell carcinoma

          -  Suitable for nephrectomy

        Exclusion Criteria:

          -  Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma
             or within the last 3 years for any other cancer

          -  Significant cardiac event within 3 months of entry

          -  Any history of coronary angioplasty or history of myocardial infarction
Clinical trial NCT00254540 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: su011248 capsule
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven renal cell carcinoma with metastases with a component of clear
             cell histology

        Exclusion Criteria:

          -  Any cellular therapy (LAK, TIL, DC), any vaccine therapy, mini-transplantation, or
             systemic molecular-targeting therapy for RCC.
Clinical trial NCT01196455 (phase 2, status: unknown status)
Conditions: breast cancer, metastasis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine and mitomycin c
SMILES: CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically/cytologically confirmed breast cancer

          -  Metastatic breast cancer, having at least one target lesion according to the RECIST
             criteria. Bone metastases, leptomeningeal disease, ascites, pleural or pericardial
             effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not
             acceptable as target lesions. Target lesions must be ≥ 10 mm longest diameter measured
             in one dimension using spiral CT, or ≥ 20 mm longest diameter measured in one
             dimension using conventional techniques. In addition to the definitions pertaining to
             the target lesion(s) from the RECIST criteria above, the target lesion(s) must not
             have been previously irradiated (newly arising lesions in previously irradiated areas
             are acceptable).

          -  Age > 18 years

          -  Signed informed consent obtained prior to initiation of any study-specific procedures
             or treatment

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast
             disease

          -  Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment

          -  Life expectancy < 3 months

          -  Not-ambulatory or with an ECOG performance status > 1

          -  Insufficient hematological, renal and hepatic functions:

          -  hemoglobin < 8.0 g/dL

          -  absolute neutrophils count (ANC) < 1.5 x 109/L

          -  platelet count < 100 x 109/L

          -  serum creatinine > 1.25 x N*

          -  total bilirubin > 2.0 x N*

          -  ASAT and/or ALAT > 2.5 x N* (in case of liver metastases > 5 x N*)

          -  alkaline phosphatase > 2.5 x N* (in case of liver metastases > 5 x N*, in case of bone
             metastases > 10 x N*) *N = upper limit of standard range

          -  Severe renal impairment [creatinine clearance < 30 mL/min (calculated according to
             cockcroft and Gault)]
Clinical trial NCT00313768 (phase 2, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: paclitaxel + carboplatin + bevacizumab, carboplatin + paclitaxel + bevacizumab + pf-3512676
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced Stage IIIb with pleural effusion or Stage IV nonsquamous non-small cell lung
             cancer

          -  ECOG Performance Status 0-1

          -  Measurable disease per RECIST criteria

        Exclusion Criteria:

          -  Squamous cell, small cell, or carcinoid lung cancer

          -  CNS metastasis

          -  Pre-existing autoimmune or antibody mediated disease

          -  Prior systemic treatment for NSCLC with chemo, immunotherapy, biologics, or
             investigation drugs
Clinical trial NCT00505921 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: campath-1h, g-csf, gm-csf, bcnu, stem cell transplant, preparative regimen for allogenic stem cell transplantation, cytarabine, etoposide, melphalan, campath, fludarabine, cyclophosphamide
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, ClCCNC(=O)N(CCCl)N=O, CCO, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must be less then 70 years old.

          -  Patients must have chemosensitive disease, having undergone at least partial remission
             with less then 10% marrow involvement by gross pathologic examination if autologous
             transplantation is considered.

          -  Newly diagnosed patients are eligible for autologous transplant. Patients in relapse
             would receive a non-myeloablative transplant if a sibling donor is available.
             Otherwise, patients would undergo autologous transplant if International Prognostic
             Index (IPI) is 0-1, or unrelated transplant if IPI is > 1.

        Exclusion Criteria:

          -  Criteria for exclusion are Human immunodeficiency virus (HIV) or Human T-lymphotropic
             virus (HTLV) seropositivity, pregnancy, cardiac ejection fraction by echo-cardiogram
             less than 40%, active central nervous system involvement, serum creatinine greater
             than 1.6 mg/dl or serum bilirubin greater than 1.5 mg/dl unless due to tumor, Absolute
             neutrophil count (ANC) less than 1,000/mm3 and platelets less than 100,000/mm3 unless
             due to tumor, performance status (ECOG scale) greater than 2, pulmonary function test-
             diffusing capacity of the Lung for Carbon Monoxide (DLCO) less than 40% of predicted,
             and severe concomitant medical or psychiatric illnesses.
Clinical trial NCT01326000 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: folfiri, ro5083945, cetuximab
SMILES: FC1=CNC(=O)NC1=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >/= 18 years of age

          -  Carcinoma of the colon and/or rectum

          -  Disease progression during or within 6 months of last dose of oxaliplatin containing
             first-line combination therapy for metastatic disease

          -  ECOG performance status 0-1

          -  Adequate hematological, renal and liver function

        Exclusion Criteria:

          -  Prior treatment with monoclonal antibody/small molecule against epidermal growth
             factor receptor (EGFR)

          -  Prior treatment with irinotecan

          -  Radiotherapy within the last 4 weeks before first dose of study drug (except for
             limited field palliative radiotherapy for bone pain relief)

          -  CNS metastasis

          -  History of or active autoimmune disorders/conditions
Clinical trial NCT00098553 (phase 2, status: completed)
Conditions: melanoma (skin)
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52
Drugs: everolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant melanoma for which no known standard or potentially
             curative therapy exists or has been proven to extend life expectancy

               -  Stage IV disease

          -  Measurable disease

               -  At least 1 lesion ≥ 20 mm by CT scan or MRI OR ≥ 10 mm by spiral CT scan

          -  No intracranial disease

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

          -  No bleeding diathesis

        Hepatic

          -  AST ≤ 3 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 3 ULN

          -  INR ≤ 1.5

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Willing to refrain from foods high in fat content

          -  No uncontrolled infection

          -  No immunosuppression from any cause (e.g., known HIV infection)

          -  No other malignancy within the past 5 years except basal cell or squamous cell skin
             cancer treated with local resection only

          -  No other severe condition that would preclude study participation or compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 4 weeks since prior immunotherapy or biologic therapy

        Chemotherapy

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and
             recovered

          -  No prior sirolimus or its analogues for any indication

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No concurrent steroids

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy to head and neck area

          -  More than 4 weeks since prior radiosurgery

          -  No prior radiotherapy to > 30% of bone marrow

          -  No concurrent radiotherapy

        Surgery

          -  Not specified

        Other

          -  At least 1 week since prior and no concurrent CYP3A4 inducers

          -  No concurrent warfarin

          -  No concurrent cytotoxic agents

          -  No other concurrent experimental drugs

          -  No other concurrent immunosuppressive therapy
Clinical trial NCT01414114 (phase 2, status: completed)
Conditions: secondary hyperparathyroidism
ICD codes: E21.1, N25.81
Drugs: etelcalcetide
SMILES: C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects provides written informed consent

          -  Screening intact PTH (iPTH) ≥ 350 pg/mL and corrected calcium ≥ 8.5 mg/dL

          -  Hemoglobin ≥ 8.5 g/dL

          -  Serum transaminases (alanine transaminase [ALT], aspartate transaminase [AST]) less
             than 2.5 times the upper limit of normal

          -  Adequate hemodialysis three times per week

        Exclusion Criteria:

          -  History or symptomatic ventricular dysrhythmias

          -  History of angina pectoris or congestive heart failure

          -  History of myocardial infarction, coronary angioplasty, or coronary artery bypass
             grafting within the past 6 months

          -  History of or treatment for seizure disorder within the last 12 months

          -  Postdialysis systolic blood pressure > 180 mmHg or diastolic blood pressure > 90 mmHg

          -  Serum magnesium below the lower limit of normal at screening
Clinical trial NCT00031551 (phase 2, status: terminated)
Conditions: stomatitis
ICD codes: B08.61, B37.0, A69.0, K12.1, B08.4
Drugs: etanercept, placebo
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    it was not feasible to recruit required sample size from two clinical sites.
  
Eligibility criteria:

        -  INCLUSION CRITERIA:

               1. Male or female oncology patients who are enrolled in participating stomatogenic
                  autologous or allogeneic PBSCT/BMT protocols, and are willing to participate in
                  this study concurrently

               2. Able to understand and sign protocol consent or assent

               3. Age 16 years or older

        EXCLUSION CRITERIA:

          1. Pregnant or lactating females

          2. Unable to follow oral rinsing directions

          3. Intubation

          4. Chronic use of medications confounding assessment of the inflammatory response
             (non-steroidal antiinflammatory drugs, antihistamines, and steroids- with the
             exception of decadron that is commonly used as an antiemetic in the PBSCT/BMT setting)

          5. Pre-existing oral infection or upper respiratory infection that might maximize the
             possibility of an infection or sepsis contributing to a drug-related adverse event

          6. Known hypersensitivity or allergic reaction to etanercept
Clinical trial NCT01223911 (phase 2, status: completed)
Conditions: inflammation, rheumatoid arthritis
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: nnc 0151-0000-0000, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  CZ: Age between 18 and 65 years (both inclusive)

          -  A diagnosis of rheumatoid arthritis of at least three months before entry in trial

          -  Active rheumatoid arthritis (RA)

          -  Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at
             least 4 weeks before trial drug administration

        Exclusion Criteria:

          -  Known or suspected allergy to trial product or related products

          -  Body mass index (BMI) less than 18.0 or more than 38.0 kg/m2 (inclusive)
Clinical trial NCT00638456 (phase 2, status: completed)
Conditions: eosinophilic esophagitis
ICD codes: K20.0
Drugs: budesonide plus prevacid, placebo plus prevacid
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic evidence of EE defined as greater than 20 eosinophils per hpf on esophageal
             biopsy

          -  Ages 1 yrs and older

          -  Ability to continue the same diet that the patient was on at the time of EGD with
             biopsy

        Exclusion Criteria:

          -  Adverse reaction or allergy to budesonide

          -  Pregnancy

          -  Chronic diseases requiring immunomodulatory therapy

          -  Use of swallowed topical corticosteroids for EE within the past 3 months

          -  Use of systemic steroids 2 months prior to study entry

          -  Upper gastrointestinal bleed within 4 months of study entry

          -  Chronic use of medications that predispose to upper gastrointestinal bleeding
             including non-steroidal anti-inflammatory medications or anticoagulants

          -  Evidence of adrenal suppression prior to study entry

          -  Evidence of concurrent eosinophilic gastritis, enteritis, colitis, or proctitis

          -  Recent changes in asthma or allergic rhinitis therapy for 3 months
Clinical trial NCT01103349 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: bi671800, placebo, montelukast
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion criteria:

          1. Signed informed consent consistent with ICH-GCP

          2. Three month history of reversible (12% and 200 mL in forced expiratory volume in one
             second - FEV1) asthma (according to GINA) with following spirometry at randomisation:
             FEV1 60%- 85%.

          3. Stable inhaled corticosteroids (iCS) dose 3 months prior to screening.

          4. Diagnosis of asthma prior to 40 years.

          5. Asthma Control Questionnaire (ACQ) at least 1.5 at randomisation.

          6. Male or female 18 to 65 years.

          7. Non-smokers or ex-smokers (less than 10 pack years history) with negative cotinine
             screen.

          8. Able to perform pulmonary function testing.

        Exclusion criteria:

          1. Significant diseases other than asthma or allergic rhinitis.

          2. Hepatic transaminases or total bilirubin greater than 1.5 ULN.

          3. Hospitalisation for asthma exacerbation or asthma related intubation within 3 months.

          4. Uncontrolled asthma on iCS + other controller.

          5. Respiratory tract infection or exacerbation within 4 weeks.

          6. FEV1 less than 40%, more than 12 puffs rescue salbutamol on more than two consecutive
             days, or asthma exacerbation during run-in period.

          7. Participation in another interventional study.

          8. Pregnant or nursing women.

          9. Women of child bearing potential not using appropriate methods of birth control as
             defined by the study protocol.
Clinical trial NCT01283594 (phase 2/phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: tozadenant (syn115) 60 mg bid, placebo, levodopa (l-dopa), tozadenant (syn115) 120 mg bid, tozadenant (syn115) 180 mg bid, tozadenant (syn115) 240 mg bid
SMILES: COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O, COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1, COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1, COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Meet Parkinson's Disease (PD) diagnosis consistent with UK PD diagnostic criteria

          -  Meet Hoehn and Yahr PD stage

          -  Good response to levodopa

          -  Stable regimen of anti-parkinson medications

          -  Are able to complete a Parkinson's disease diary

          -  If of childbearing potential(male and female), use an acceptable method of birth
             control

          -  Able and willing to sign an IRB/IEC approved informed consent

          -  Able and willing to understand study requirements, follow study instructions, attend
             all visits and undergo all planned tests.

        Exclusion Criteria:

          -  Secondary or atypical Parkinson's

          -  Neurosurgical intervention for Parkinson's disease

          -  Treatment with apomorphine

          -  Treatment with anti-psychotic drugs

          -  Other abnormal findings on physical or neuro exam or history that in the opinion of
             the investigator would make subject unsuitable for the study or prejudice safety and
             efficacy evaluation

          -  MMSE less than 26

          -  Subjects with untreated or uncontrolled current episode of major depression

          -  Receipt of any anti-psychotic drugs greater than 1 month in the past 5 years or any
             exposure in past year (except for quetiapine at doses <100mg per day)

          -  Women pregnant or lactating

          -  History of hepatitis, cholangitis

          -  Untreated or uncontrolled hypothyroidism or hyperthyroidism

          -  Drops in blood pressure requiring medication to maintain blood pressure

          -  Any clinically significant out of range laboratory evaluations

          -  Known sensitivity to the study medication or its components

          -  Suicide ideation or type 4 or type 5 on the Columbia suicide severity rating scale

          -  Finding of malignant melanoma on full body skin exam

          -  Impulse disorder conditions